| |
|
|
|
|
|
 |
| |
|
¾Æ¹Ì·ÎÁ¤(¿°»ê¾Æ¹Ì·Î¶óÀ̵å) Amilo Tab.
|
Àü¹®ÀǾàǰ | ±Þ¿©
|
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
 | º´¿ë±Ý±â |
|
|
|
|
|
|
 |
Á¦Ç°º° ÀӺαݱ⠰í½Ã |
|
|
|
1µî±Þ: ¿øÄ¢Àû »ç¿ë±Ý±â / 2µî±Þ: ¸íÈ®ÇÑ ÀÓ»óÀû ±Ù°Å ¶Ç´Â »çÀ¯°¡ ÀÖ´Â °æ¿ì ºÎµæÀÌÇÏ°Ô »ç¿ë / Mµî±Þ: ÀÓ»óÀû»óȲ¿¡ µû¶ó 1µî±Þ ¶Ç´Â 2µî±ÞÀ¸·Î ºÐ·ùµÇ´Â ¼ººÐ
| ¼ººÐ¸í |
¼ººÐÄÚµå |
±Ý±âµî±Þ |
°í½Ã¹øÈ£ |
°í½ÃÀÏÀÚ |
ºñ°í |
| amiloride HCl |
106901ATB |
2 |
20160155 |
20161230 |
Ç÷¾×·® °¨¼Ò, Ç÷¾×Á¡µµ Áõ°¡ ¹× ŹÝÇ÷·ù·® °¨¼Ò¿Í °ü·Ã.ÅÂ¾Æ¿Í ½Å»ý¾ÆÀÇ È²´Þ, žÆÀÇ °ñ¼ö¾ïÁ¦, Ç÷¼ÒÆÇ °¨¼Ò º¸°í. |
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
646800920[A03802121]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\49 ¿ø/1Á¤(2017.02.01)(ÇöÀç¾à°¡)
\49 ¿ø/1Á¤(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹ÌȲ»öÀÇ ¿øÇüÁ¤Á¦. [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
100Á¤/º´, 1000Á¤/º´ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 5¹Ð¸®±×·¥ |
1000 Á¤ |
º´ |
8806468009201 |
8806468009232 |
|
| 5¹Ð¸®±×·¥ |
100 Á¤ |
º´ |
8806468009201 |
8806468009225 |
|
| 5¹Ð¸®±×·¥ |
30 Á¤ |
º´ |
8806468009201 |
8806468009218 |
|
|
| ÁÖ¼ººÐÄÚµå |
106901ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¿ïÇ÷¼º½ÉºÎÀü, ½ÅÀå±â´ÉÀÌ Á¤»óÀÎ °íÇ÷¾Ð, º¹¼ö¸¦ ¼ö¹ÝÇÑ °£°æº¯
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
ÀÌ ¾àÀº ´Üµ¶À¸·Î Åõ¿©ÇÒ ¼ö ÀÖÀ¸³ª Ä¡¾ÆÁþ ¶Ç´Â Ä®·ý ¹è¼³¼º ÀÌ´¢Á¦¿Í º´¿ëÅõ¿©ÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
¡Û ¼ºÀÎ
1. ¿ïÇ÷¼º½ÉºÎÀü : ¿°»ê¾Æ¹Ð·Î¶óÀ̵å·Î¼ 1ÀÏ 5-10§·À» °æ±¸Åõ¿©ÇÑ´Ù.
2. °íÇ÷¾Ð : ÀÌ ¾àÀ¸·Î¼ 1ÀÏ 5-10§·À» Ç÷¾Ð°ÇÏÁ¦¿Í º´¿ëÅõ¿©ÇÑ´Ù.
3. º¹¼ö¸¦ ¼ö¹ÝÇÑ °£°æº¯ : ÀÌ ¾àÀ¸·Î¼ 1ÀÏ 5§·ÀÇ Àú¿ë·®°ú ´Ù¸¥ ÀÌ´¢Á¦ÀÇ Àú¿ë·®°ú º´¿ëÅõ¿©ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ±Ý±â |
1) °íÄ®·ýÇ÷Áõ(Ç÷Áß Ä®·ý³óµµ°¡ 5.5 mmol/§¤ÀÌ»ó) ȯÀÚ
2) ´Ù¸¥ Ä®·ýº¸Á¸¼º ¾à¹° ¶Ç´Â Ä®·ýÀ» Åõ¿©¹Þ°í Àִ ȯÀÚ
3) ¹«´¢ ȯÀÚ
4) ±Þ¡¤¸¸¼º ½ÅºÎÀü ȯÀÚ
5) ÁßÁõÀÇ ÁøÇ༺ ½ÅÁúȯ ȯÀÚ
6) ´ç´¢º´¼º ½ÅÁõ ȯÀÚ
7) ÀÌ ¾à¿¡ °ú¹ÎÁõ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ
8) ¼Ò¾Æ
|
| ½ÅÁßÅõ¿© |
1) ´ç´¢º´ ȯÀÚ
2) ´ë»ç¼º, È£Èí¼º »êÁõ ȯÀÚ
3) ÀüÇØÁú ºÒ±ÕÇü°ú °¡¿ªÀû Ç÷´¢ÀÇ Áõ°¡°¡ ³ªÅ¸³ª´Â ȯÀÚ
4) °£°æº¯ ȯÀÚ(°£¼º È¥¼ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
5) ½Å±â´ÉÀå¾Ö ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) Àü½Å : µÎÅë, ¼è¾à, ÇÇ·Î, ¹èÅë(back pain), °æ°ßÅë, »çÁöµ¿Åë µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ½ÉÇ÷°ü°è : Çù½ÉÁõ, ±â¸³¼º ÀúÇ÷¾Ð, ºÎÁ¤¸Æ, ½É°èÇ×Áø, ºÎºÐ ¹æ½ÇºÐ¸® ȯÀÚÀÇ ¿ÏÀü ¹æ½ÇºÐ¸®·ÎÀÇ ÁøÇà µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼Òȱâ°è : ½Ä¿åºÎÁø, ±¸¿ª, ±¸Åä, ¼³»ç, º¯ºñ, º¹Åë, À§Àå°üÃâÇ÷, Ȳ´Þ, ±¸°¥, ¼ÒȺҷ®, º¹ºÎÆØ¸¸°¨, À§ÀåÀå¾Ö, °¡½¿¾²¸² µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) ´ë»çÀÌ»ó : Ç÷Áß Ä®·ý³óµµÀÇ »ó½Â(5.5mmol/§¤ÀÌ»ó), Àú³ªÆ®·ýÇ÷Áõ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) ÇǺΠ: °¡·Á¿ò, ¹ßÁø, ±¸°°ÇÁ¶, ¿øÇüÅ»¸ð µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) °ñ°Ý±Ù°è : ±Ù°æ·Ã, °üÀýÅë µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) Á¤½Å½Å°æ°è : ¾îÁö·¯¿ò, °¨°¢ÀÌ»ó, ÁøÀü, ³úÁúȯ, ½Å°æ°ú¹Î, Á¤½ÅÂø¶õ, ºÒ¸éÁõ, ¼º¿å°¨Åð, ¿ì¿ïÁõ, Á¹À½ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) È£Èí±â°è : ±âħ, È£Èí°ï¶õ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
9) °¨°¢±â°è : ºñÃæÇ÷, ½Ã°¢Àå¾Ö, ¾È³»¾Ð Áõ°¡, ÀÌ¸í µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
10) ºñ´¢»ý½Ä±â°è : ¹ß±âºÎÀü, ´Ù´¢, ¹è´¢Àå¾Ö, ¹æ±¤°æ·Ã, ºó´¢ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
11) ±âŸ : ¿©¼ºÇüÀ¯¹æÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ½ÅÀåÀ» ÅëÇÑ ¸®Æ¬¹è¼³ÀÌ °¨¼ÒµÇ¾î ¸®Æ¬¿¡ ÀÇÇÑ ½Éµ¶¼º ¹× ½Å°æµ¶¼ºÀÌ Áõ°¡µÉ ¼ö ÀÖÀ¸¹Ç·Î º´¿ëÅõ¿©¸¦ ÇÇÇÑ´Ù.
2) ´Ù¸¥ ÀÌ´¢Á¦¿Í ÀÌ ¾àÀ» º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â Àú³ªÆ®·ýÇ÷Áõ, ÀúÄ®·ýÇ÷Áõ ¹× Àú¿°¼ÒÇ÷ÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ƯÈ÷ º¹¼ö¸¦ ¼ö¹ÝÇÑ °£°æº¯ ȯÀÚ ¹× ´ë»ç¼º ¾ËÄ®¸®Áõ, ºÎÁ¾ ȯÀÚ´Â ´Ù¸¥ ÀÌ´¢Á¦¿Í º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â Ç÷Áß¿ä»êÀÌ »ó½ÂÇÒ ¼ö ÀÖÀ¸¹Ç·Î Ç÷Áß¿ä»ê ¹× ÀüÇØÁú ³óµµ¸¦ ¸ð´ÏÅÍÇÑ´Ù.
3) ACE ÀúÇØÁ¦ ¹× Ä®·ýÇÔÀ¯ ½Äǰ°ú º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â °íÄ®·ýÇ÷ÁõÀÇ À§ÇèÀÌ Áõ°¡ÇÑ´Ù. ±×·¯¹Ç·Î ÀúÄ®·ýÇ÷Áõ ȯÀÚ¿¡°Ô ÀÌ·¯ÇÑ ¾à¹°À» º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â Ç÷Áß Ä®·ý³óµµ¸¦ ½ÅÁßÈ÷ ¸ð´ÏÅÍÇÑ´Ù.
4) ÀÌ ¾à¹°À» Ä¡¾ÆÁþ°è ÀÌ´¢Á¦ ¹× Ŭ·Î¸£ÇÁ·ÎÆÄ¹Ìµå¿Í º´¿ëÅõ¿©Çϸé Àú³ªÆ®·ýÇ÷Áõ À§ÇèÀÌ Áõ°¡µÈ´Ù.
5) ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°ÁøÅëÁ¦¿Í º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â ÀÌ ¾àÀÇ ÀÌ´¢ÀÛ¿ëÀÌ °¨¼ÒµÇ¹Ç·Î ÁÖÀÇÇÑ´Ù
6) ¸ÞÆ®Æ÷¸£¹Î¿¡ ÀÇÇÑ Á¥»êÇ÷ÁõÀÇ À§ÇèÀÌ ÀÖÀ¸¹Ç·Î Ç÷ÁßÅ©·¹¾ÆÆ¼´ÑÄ¡°¡ ³²¼º 1.5§·/§£ÀÌ»ó, ¿©¼º 12§·/§£ ÀÌ»óÀÏ °æ¿ì¿¡´Â ¸ÞÆ®Æ÷¸£¹Î°ú ÀÌ ¾àÀ» º´¿ë Åõ¿©ÇÏÁö ¾Ê´Â´Ù.
7) ÀÌ´¢Á¦¿¡ ÀÇÇÑ Ã¼¾×°¨¼ÒȯÀÚ¿¡°Ô ¿ä¿ÀµåÇÔÀ¯¹°ÁúÀ» º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â Åõ¿©Àü¿¡ ¼öºÐÀ» °ø±ÞÇÑ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
646800920[A03802121]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\49 ¿ø/1Á¤(2017.02.01)(Ãֽžడ)
\49 ¿ø/1Á¤(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
¹ÌȲ»öÀÇ ¿øÇüÁ¤Á¦.
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| ´ëü°ü·Ã |
´ëÁ¶¾à |
| Æ÷À塤À¯Åë´ÜÀ§ |
100Á¤/º´, 1000Á¤/º´ |
| º¸°ü¹æ¹ý |
±â¹Ð¿ë±â |
µ¿ÀÏÁÖ¼ººÐÄÚµå °Ë»ö¼øÀ§ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Brandname Á¤º¸ |
Amiloride HCl
Brand Names/Synonyms
- AMR
- Amilorida [INN-Spanish]
- Amiloride HCL
- Amiloride hydrochloride
- Amiloridum [INN-Latin]
- Amipramidin
- Amipramizid
- Amipramizide
- Amiprazidine
- Guanamprazin
- Guanamprazine
- Midamor
- Amiloride hydrochloride hydrate
Brand Name Mixtures
- Alti-Amiloride HCTZ (Amiloride Hcl + Hydrochlorothiazide)
- Ami-Hydro Tab (Amiloride Hcl + Hydrochlorothiazide)
- Apo-Amilzide Tab (Amiloride Hcl + Hydrochlorothiazide)
- Gen-Amilazide (Amiloride Hcl + Hydrochlorothiazide)
- Moduret (Amiloride Hcl + Hydrochlorothiazide)
- Novamilor Tab USP (Amiloride Hcl + Hydrochlorothiazide)
- Nu-Amilzide 5/50 mg Tab (Amiloride Hcl + Hydrochlorothiazide)
- Riva-Amilzide 5/50 mg (Amiloride Hcl + Hydrochlorothiazide)
Chemical IUPAC Name3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Dµî±Þ
(Àӽżº °íÇ÷¾Ð¿¡ Åõ¿©½Ã )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
[potassium chloride]
[potassium citrate]
[spironolactone]
[tacrolimus hydrate (as tacrolimus)]
[tacrolimus hydrate (as tacrolimus)]
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Amiloride¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Amiloride¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Amiloride works by inhibiting sodium reabsorption in the distal convoluted tubules and collecting ducts in the kidneys by binding to the amiloride-sensitive sodium channels. This promotes the loss of sodium and water from the body, but without depleting potassium. Amiloride exerts its potassium sparing effect through the inhibition of sodium reabsorption at the distal convoluted tubule, cortical collecting tubule and collecting duct; this decreases the net negative potential of the tubular lumen and reduces both potassium and hydrogen secretion and their subsequent excretion. Amiloride is not an aldosterone antagonist and its effects are seen even in the absence of aldosterone.
|
| Pharmacology |
Amiloride¿¡ ´ëÇÑ Pharmacology Á¤º¸ Amiloride, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents. It is an antihypertensive, potassium-sparing diuretic that was first approved for use in 1967 and helps to treat hypertension and congestive heart failure. The drug is often used in conjunction with thiazide or loop diuretics. Due to its potassium-sparing capacities, hyperkalemia (high blood potassium levels) are occasionally observed in patients taking amiloride. The risk is high in concurrent use of ACE inhibitors or spironolactone. Patients are also advised not to use potassium-containing salt replacements.
|
| Metabolism |
Amiloride¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Half-life |
Amiloride¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Plasma half-life varies from 6 to 9 hours.
|
| Absorption |
Amiloride¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed following oral administration.
|
| Biotransformation |
Amiloride¿¡ ´ëÇÑ Biotransformation Á¤º¸ Amiloride is not metabolized by the liver but is excreted unchanged by the kidneys.
|
| Toxicity |
Amiloride¿¡ ´ëÇÑ Toxicity Á¤º¸ No data are available in regard to overdosage in humans. The oral LD50 of amiloride hydrochloride (calculated as the base) is 56 mg/kg in mice and 36 to 85 mg/kg in rats, depending on the strain. The most likely signs and symptoms to be expected with overdosage are dehydration and electrolyte imbalance.
|
| Drug Interactions |
Amiloride¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Benazepril Increased risk of hyperkaliemiaCandesartan Increased risk of hyperkaliemiaCaptopril Increased risk of hyperkaliemiaEnalapril Increased risk of hyperkaliemiaEplerenone The association presents an ncreased risk of hyperkaliemiaEprosartan Increased risk of hyperkaliemiaFosinopril Increased risk of hyperkaliemiaIrbesartan Increased risk of hyperkaliemiaLisinopril Increased risk of hyperkaliemiaLosartan Increased risk of hyperkaliemiaMoexipril Increased risk of hyperkaliemiaQuinapril Increased risk of hyperkaliemiaQuinidine Decreases the antiarrhythmic effect of quinidineRamipril Increased risk of hyperkaliemiaTelmisartan Increased risk of hyperkaliemiaTrandolapril Increased risk of hyperkaliemiaValsartan Increased risk of hyperkaliemiaCilazapril Increased risk of hyperkaliemiaDihydroquinidine barbiturate Decreases the antiarrhythmic effect of quinidineForasartan Increased risk of hyperkaliemiaPerindopril Increased risk of hyperkaliemiaPolystyrene sulfonate Antagonism of actionPotassium Increased risk of hyperkaliemiaQuinidine barbiturate Decreases the antiarrhythmic effect of quinidineSaprisartan Increased risk of hyperkaliemiaSpirapril Increased risk of hyperkaliemiaTasosartan Increased risk of hyperkaliemia
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Amiloride¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid drastic changes in dietary habit.Avoid salt substitutes containing potassium.Take with food to reduce irritation.Avoid natural licorice.
|
| Drug Target |
[Drug Target]
|
| Description |
Amiloride¿¡ ´ëÇÑ Description Á¤º¸ A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
|
| Drug Category |
Amiloride¿¡ ´ëÇÑ Drug_Category Á¤º¸ DiureticsSodium channel blockers
|
| Smiles String Canonical |
Amiloride¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1
|
| Smiles String Isomeric |
Amiloride¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ N\C(N)=N/C(=O)C1=C(N)N=C(N)C(Cl)=N1
|
| InChI Identifier |
Amiloride¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)/f/h8-11H2
|
| Chemical IUPAC Name |
Amiloride¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|